Pharmacologic approaches to the treatment of Huntington's disease.
about
The P42 peptide and Peptide-based therapies for Huntington's diseaseDeveloping stem cell therapies for juvenile and adult-onset Huntington's diseaseEffectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohortCurrent Pharmacological Approaches to Reduce Chorea in Huntington's Disease.Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells.Characterising Upper Limb Movements in Huntington's Disease and the Impact of Restricted Visual Cues.Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline.Two decades of Huntington disease testing: patient's demographics and reproductive choices.Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.The role of dopamine in Huntington's disease.Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.Emotional dysfunctions in neurodegenerative diseases.Huntington's disease: Molecular basis of pathology and status of current therapeutic approachesAstrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease.Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity.Recent advances in the management of choreas.Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.Behavioral testing of minipigs transgenic for the Huntington gene-A three-year observational study.Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington's disease models.The pridopidine paradox in Huntington's disease.
P2860
Q26764930-5C53B58E-8A36-4C5B-9BEB-223015AF659EQ26799722-09792095-74C1-4521-9B71-C6DD0C5ADD3EQ28538703-2476D7F0-1232-4160-AD91-1FFC70FC4556Q34547558-7EB961A6-F7AA-4024-900C-A7C8E54B4DB8Q35052612-8E3803D6-66A7-4D50-8075-33EEF41A8927Q35738853-5A12885E-E740-4120-A592-5E9DE527CA0FQ38106927-3C428C78-CA97-4AD3-B0AF-2A80910B9942Q38109547-9F841B22-A565-40F4-A847-1803E35C98AEQ38121068-0BEEE66C-D59C-44EC-9D92-3B9FD2BCE448Q38223504-311BB3C8-4F59-4B77-B196-F11593390A3CQ38244078-7DB41AE6-51DE-487D-BAFE-8C0CA7E791F9Q38248689-B38BE41C-5A5A-407F-9801-1A6E50AAF82EQ38502761-41A935E7-2ECD-4AB6-AD9D-09E412F7C8A2Q38815118-1F2B5B73-5FB2-4697-8C36-4F5481BF03A5Q38839272-F58ECEF1-3CD8-4126-A11B-285A7C44D052Q39772092-71B94247-4C58-499C-A4C9-BADEE3240847Q42143817-510C7399-C98C-4341-BCAE-C1A4819B5A72Q42666223-23B7D473-90C7-462F-9B71-B330D27B2C1DQ42708331-7E55708E-AA65-42C9-856F-920F91B61BEEQ43494697-25684706-0C8C-4023-8F77-3C0A3777C433Q45294030-359095D7-5F54-4FBE-9C8C-CAE0211BF1DF
P2860
Pharmacologic approaches to the treatment of Huntington's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacologic approaches to the treatment of Huntington's disease.
@en
Pharmacologic approaches to the treatment of Huntington's disease.
@nl
type
label
Pharmacologic approaches to the treatment of Huntington's disease.
@en
Pharmacologic approaches to the treatment of Huntington's disease.
@nl
prefLabel
Pharmacologic approaches to the treatment of Huntington's disease.
@en
Pharmacologic approaches to the treatment of Huntington's disease.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacologic approaches to the treatment of Huntington's disease.
@en
P2093
Andrew McGarry
Charles S Venuto
P2860
P356
10.1002/MDS.23953
P407
P577
2011-10-13T00:00:00Z